Abstract:Tiejun Gong, 1 Yuerong Shuang 2 1 Institute of Hematology and Oncology, Harbin the First Hospital, Harbin, 150010, People's Republic of China; 2 Department of Lymphatic Hematology and Oncology, Jiangxi Cancer Hospital, Nanchang, 330029, People's Republic of China Correspondence: Yuerong Shuang Department of Lymphatic Hematology and Oncology, Jiangxi Cancer Hospital, No. 519 Beijingdong Road, Nanchang, Jiangxi, 330029, People's Republic of China Tel +86-791-8831378 Email Background: The eukaryotic translation elongation factor 1A1 (EEF1A1) participates in protein translation and has been reported to be involved in tumor progression such as hepatocellular carcinoma. Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy in adults. In the present study, we aimed to detect the expression of EEF1A1 in DLBCL and to analyze its relationship with prognosis. Methods: We reviewed medical records of DLBCL patients in our hospital and evaluated their expression level of EEF1A1 in tumor tissues using immunohistochemical (IHC) assay. The Chi-square method was used for correlation analysis. The Kaplan–Meier method with Log rank test was used for univariate analysis. Cox proportional hazards model was used for multivariate analysis. Cellular and mice models were introduced to validate its oncogenic role. Results: EEF1A1 expression in tumor cells was higher in certain DLBCL cases. Patients with higher EEF1A1 expression were more likely to have advanced tumor stage and poorer 5-year overall survival (OS) rates. EEF1A1 expression in tumor cells was an independent risk predictor for OS (P < 0.05). Cellular assays demonstrated that EEF1A1-shRNA significantly inhibited lymphoma cell proliferation. The study of xenografts further verified the effect of EEF1A1-shRNA on suppressing tumor growth in vivo. Conclusion: EEF1A1 positivity predicts short survival in DLBCL patients. For patients with higher EEF1A1 expression, more strategy such as anti-EEF1A1 antibody treatment should be developed. Keywords: diffuse large B-cell lymphoma, prognosis, EEF1A1, proliferation Characterized by growing tumor mass in single or multiple lymph nodes as well as extranodal sites, 1 diffuse large B‐cell lymphoma (DLBCL) is the most common type of non‐Hodgkin lymphoma (NHL), accounting for 30% of NHL cases worldwide. 2 There are approximately 15,000 newly diagnosed DLBCL cases in the United States, 3 and about 25,000 new cases in China each year. 4 Although more than 80% of DLBCL patients may achieve a complete remission under immunochemotherapy, a significant minority (20% to 25%) of these patients will suffer with relapse. 5 The increasing incidence and unsatisfied prognosis are attracting more and more attentions. Therefore, understanding the oncogenesis mechanism and progression regulators of DLBCL are urgently needed for prognosis prediction and therapy development. Eukaryotic elongation factor-1 (EF1) contains four subunits, EF1α, EF1β, EF1γ, and EF1δ. 6 Eukaryotic translation elongation factor 1 alpha 1 (EEF1A1) is a predominant isoform of the EEF1α complex, which participates in tRNA delivery by promoting the GTP-dependent binding of aminoacyl-tRNA to the A-site of ribosomes. 7 EEF1A1 is ubiquitously expressed in many tissues due to its critical function in protein synthesis. Besides protein synthesis, EEF1A1 plays roles in cytoskeleton organization, cell apoptosis, stabilizing RNAs, etc. 8 Ditzel et al identified EEF1A1 as an autoantibody in about 66% of the patients with Felty syndrome, an disorder characterized by autoimmune diseases such as rheumatoid arthritis and splenomegaly. 9 Dysregulated EEF1A1 has been identified in many diseases. For example, hyperexpression of EEF1A1 was reported in spinal and bulbar muscular atrophy and amyotrophic lateral sclerosis. 10 In contrast, a hypoexpression of EEF1A1 is observed during myocardial infarction and may be involved in cardiovascular disorders. 11 Of note, the potential role of EEF1A1 in tumor progression has been reported in certain malignancies. For example, Grassi et al reported a higher mRNA level of EEF1A1 in hepatocellular carcinoma cell lines compared to normal liver cells. 12 A similar conclusion was obtained based on the protein level of EEF1A1 in clinical resected liver cancer tissues. 13 Consistently, EEF1A1 was highly expressed in clear cell renal cell carcinomas (RCC) and associated with poor clinical outcomes. Knockdown of EEF1A1 impaired the viability of RCC cells. 14 In contrast, EEF1A1 seems to play tumor suppressing roles in colon cancer and breast cancer. High expression of EEF -Abstract Truncated-

Tumor Necrosis Factor- (cid:1) Downregulates Endothelial Nitric Oxide Synthase Mrna Stability Via Translation Elongation Factor 1- (cid:1) 1

TNF-alpha Downregulates Endothelial Nitric Oxide Synthase mRNA Stability via Translation Elongation Factor 1-alpha 1

Tumor Necrosis Factor-Alpha Downregulates Endothelial Nitric Oxide Synthase Mrna Stability Via Translation Elongation Factor 1-Alpha 1

Post-Transcriptional Regulation of Endothelial Nitric Oxide Synthase Expression by Polypyrimidine Tract–Binding Protein 1

Shear Stress Induction of the Endothelial Nitric Oxide Synthase Gene is Calcium-Dependent but Not Calcium-Activated.

Knockout of the Tumor Necrosis Factor a Receptor 1 Gene Can Up-Regulate Erythropoietin Receptor During Myocardial Ischemia-Reperfusion Injury in Mice.

Abstract 256: Post-transcriptional Regulation of Endothelial Nitric Oxide Synthase Expression by Translation Elongation Factor 1-Alpha

Endothelin-Converting Enzyme-1 (ECE-1) Is Post-Transcriptionally Regulated by Alternative Polyadenylation

Nuclear eNOS interacts with and S-nitrosates ADAR1 to modulate endothelial gene expression

eIF3 mRNA selectivity profiling reveals eIF3k as a cancer-relevant regulator of ribosome content

14-3-3 Epsilon Dynamically Interacts with Key Components of Mitogen-Activated Protein Kinase Signal Module for Selective Modulation of the Tnf-Alpha-Induced Time Course-Dependent Nf-Kappa B Activity

Exogenous, but not Endogenous Nitric Oxide Inhibits Adhesion Molecule Expression in Human Endothelial Cells

Commutative regulation between endothelial NO synthase and insulin receptor substrate 2 by microRNAs.

Perturbations in eIF3 subunit stoichiometry alter expression of ribosomal proteins and key components of the MAPK signaling pathways.

Proteomic profiling of eIF3a conditional knockout mice

Understanding functions of eEF1 translation elongation factors beyond translation. A proteomic approach

5’ UTR recruitment of eIF4GI or DAP5 drives cap-independent translation for a subset of human mRNAs

RNA N 6 -methyladenosine modulates endothelial atherogenic responses to disturbed flow in mice

Expression and Clinical Value of Eukaryotic Translation Elongation Factor 1A1 (EEF1A1) in Diffuse Large B Cell Lymphoma

Role of Isoprenylcysteine Carboxyl Methyltransferase in Tumor Necrosis Factor-Alpha Stimulation of Expression of Vascular Cell Adhesion Molecule-1 in Endothelial Cells.

Eif3 Associates with 80S Ribosomes to Promote Translation Elongation, Mitochondrial Homeostasis, and Muscle Health